BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26881708)

  • 1. Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases.
    Mckenzie-Nickson S; Bush AI; Barnham KJ
    Curr Top Med Chem; 2016; 16(27):3058-3068. PubMed ID: 26881708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological metals and metal-targeting compounds in major neurodegenerative diseases.
    Barnham KJ; Bush AI
    Chem Soc Rev; 2014 Oct; 43(19):6727-49. PubMed ID: 25099276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Structural Chemistry Perspective on the Antimalarial Properties of Thiosemicarbazone Metal Complexes.
    Summers KL
    Mini Rev Med Chem; 2019; 19(7):569-590. PubMed ID: 30324878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-Derived Blood-Brain Barrier Model for Screening Copper Bis(thiosemicarbazone) Complexes as Potential Therapeutics in Alzheimer's Disease.
    Wasielewska JM; Szostak K; McInnes LE; Quek H; Chaves JCS; Liddell JR; Koistinaho J; Oikari LE; Donnelly PS; White AR
    ACS Chem Neurosci; 2024 Apr; 15(7):1432-1455. PubMed ID: 38477556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptides and their Metal Complexes in Neurodegenerative Diseases: from Structural Studies to Nanomedicine Prospects.
    Trapani G; Satriano C; La Mendola D
    Curr Med Chem; 2018 Feb; 25(6):715-747. PubMed ID: 29076411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transition metals and metal complexes in autophagy and diseases.
    Luo Y; Fu Y; Huang Z; Li M
    J Cell Physiol; 2021 Oct; 236(10):7144-7158. PubMed ID: 33694161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antioxidant properties of flavonoid metal complexes and their potential inclusion in the development of novel strategies for the treatment against neurodegenerative diseases.
    Rodríguez-Arce E; Saldías M
    Biomed Pharmacother; 2021 Nov; 143():112236. PubMed ID: 34649360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minding metals: tailoring multifunctional chelating agents for neurodegenerative disease.
    Perez LR; Franz KJ
    Dalton Trans; 2010 Mar; 39(9):2177-87. PubMed ID: 20162187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zn II(atsm) is protective in amyotrophic lateral sclerosis model mice via a copper delivery mechanism.
    McAllum EJ; Roberts BR; Hickey JL; Dang TN; Grubman A; Donnelly PS; Liddell JR; White AR; Crouch PJ
    Neurobiol Dis; 2015 Sep; 81():20-4. PubMed ID: 25766674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metal attenuating therapies in neurodegenerative disease.
    Mot AI; Wedd AG; Sinclair L; Brown DR; Collins SJ; Brazier MW
    Expert Rev Neurother; 2011 Dec; 11(12):1717-45. PubMed ID: 22091597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aryl- and heteroaryl-thiosemicarbazone derivatives and their metal complexes: a pharmacological template.
    Moorthy NS; Cerqueira NM; Ramos MJ; Fernandes PA
    Recent Pat Anticancer Drug Discov; 2013 May; 8(2):168-82. PubMed ID: 22963201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transition metal complexes as imaging or therapeutic agents for neurodegenerative diseases.
    Ma DL; Wu C; Li G; Yung TL; Leung CH
    J Mater Chem B; 2020 Jun; 8(22):4715-4725. PubMed ID: 32100789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic activity of expanded coordination bis-thiosemicarbazones and copper complexes thereof.
    Akladios FN; Andrew SD; Parkinson CJ
    J Biol Inorg Chem; 2016 Dec; 21(8):931-944. PubMed ID: 27645502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of Amyotrophic Lateral Sclerosis, Parkinson's and Alzheimer's diseases helps further define pathology of the novel paradigm for Alzheimer's with heavy metals as primary disease cause.
    Cavaleri F
    Med Hypotheses; 2015 Dec; 85(6):779-90. PubMed ID: 26604027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copper complexes of bis(thiosemicarbazones): from chemotherapeutics to diagnostic and therapeutic radiopharmaceuticals.
    Paterson BM; Donnelly PS
    Chem Soc Rev; 2011 May; 40(5):3005-18. PubMed ID: 21409228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders.
    Wilkins HM; Morris JK
    Curr Pharm Des; 2017; 23(5):731-752. PubMed ID: 28034353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative Stress and Antioxidants in Neurological Diseases: Is There Still Hope?
    Carvalho AN; Firuzi O; Gama MJ; Horssen JV; Saso L
    Curr Drug Targets; 2017 Mar; 18(6):705-718. PubMed ID: 27033198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiosemicarbazones: the new wave in cancer treatment.
    Kalinowski DS; Quach P; Richardson DR
    Future Med Chem; 2009 Sep; 1(6):1143-51. PubMed ID: 21425997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting mitochondrial metal dyshomeostasis for the treatment of neurodegeneration.
    Liddell JR
    Neurodegener Dis Manag; 2015 Aug; 5(4):345-64. PubMed ID: 26295717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coordination of Fe(III), Co(II), Ni(II), Cu(II), Zn(II), Cd(II), Hg(II), Pd(II) and Pt(II) with 2,5-hexanedione bis(thiosemicarbazone), HBTS: crystal structure of cis-[Pd(HBTS)]Cl2 and 1-(2,5-dimethyl-1H-pyrrol-yl)-thiourea.
    Jeragh B; El-Asmy AA
    Spectrochim Acta A Mol Biomol Spectrosc; 2014 Sep; 130():546-52. PubMed ID: 24813284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.